Resources Repository
-
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Cost-Effectiveness Analysis | Health/Medicine | North America | Priority Setting/Ethics | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | Global -
ArticlePublication 2022Cost-Effectiveness of Masked Hypertension Screening and Treatment
The study assessed the health and economic outcomes of screening and treating masked hypertension in …
The study assessed the health and economic outcomes of screening and treating masked hypertension in U.S. adults using the Cardiovascular Disease (CVD) Policy Model, a microsimulation model. The model simulated 100,000 adults suspected of having masked hypertension (office blood pressure [BP] of 120–129/<80 mm Hg, not on antihypertensive medications, and without a history of CVD). Interventions included: usual care alone, usual care with ambulatory BP monitoring (ABPM), and usual care with home BP monitoring (HBPM).…
Cost-Effectiveness Analysis | Health/Medicine | North America | Microsimulation | Chronic Disease/Risk | Clinical Care -
ArticlePublication 2022Duration & Cost-Effectiveness of Hepatocellular Carcinoma Surveillance in Hepatitis C Patients After Viral Eradication
This study assesses the cost-effectiveness of biannual surveillance for hepatocellular carcinoma (HCC) in patients cured …
This study assesses the cost-effectiveness of biannual surveillance for hepatocellular carcinoma (HCC) in patients cured of hepatitis C virus (HCV) using oral direct-acting antivirals (DAAs). A microsimulation model of HCC natural history in individuals with HCV-related advanced fibrosis or cirrhosis post-DAAs was developed, integrating data on HCC incidence, tumor progression, surveillance adherence, and health state costs/utilities. Biannual ultrasound and alpha-fetoprotein surveillance were compared to no surveillance over varying durations (5 years to lifetime). Results indicate…
Cost-Effectiveness Analysis | Health/Medicine | North America | Microsimulation | Chronic Disease/Risk -
ArticlePublication 2022Cost-Effectiveness of Screening for Atrial Fibrillation Using Wearable Devices
This economic evaluation assesses the cost-effectiveness of atrial fibrillation (AF) screening strategies, particularly utilizing wrist-worn …
This economic evaluation assesses the cost-effectiveness of atrial fibrillation (AF) screening strategies, particularly utilizing wrist-worn wearable devices, to prevent strokes. Conducted using a microsimulation decision-analytic model, the study spans from September 8, 2020, to May 23, 2022, incorporating 30 million simulated individuals representative of the US population aged 65 years or older. Eight screening strategies, including six employing wrist-worn devices and two using traditional methods, were compared against no screening. Results indicate that all wrist-worn…
Cost-Effectiveness Analysis | Health/Medicine | North America | Microsimulation | Chronic Disease/Risk -
ArticlePublication 2021Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops
The Los Angeles Barbershop Blood Pressure Study (LABBPS) examined the effectiveness and cost of a …
The Los Angeles Barbershop Blood Pressure Study (LABBPS) examined the effectiveness and cost of a one-year pharmacist-led hypertension care intervention in Black-owned barbershops in Los Angeles County, focused on non-Hispanic Black men with uncontrolled hypertension. Using a discrete event simulation, the researchers projected the 10-year health outcomes and health care costs associated with the intervention compared to a control group. The costs and quality-adjusted life-years (QALYs) were calculated from a health care sector perspective, with…
Cost-Effectiveness Analysis | Health/Medicine | North America | Mathematical Models | Chronic Disease/Risk | Clinical Care -
ArticlePublication 2021Individual and Social Determinants of COVID-19 Vaccine Uptake
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using …
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using national survey data collected before vaccines were available in the U.S. Of note, individuals under the federal poverty level and racial and ethnic minorities were oversampled. Outcomes included the likelihood of vaccinating self and dependents (e.g., children). Independent variables included perceptions of risk, exposure to different media for COVID-19 news, political party identification, confidence in scientists and social determinants of…
Evidence Synthesis | Health/Medicine | North America | Health Outcomes | Infectious Diseases | Social Determinants | Policy/Regulation | Clinical Care | Culture/Society | Science/Technology -
ArticlePublication 2021COVID-19 Vaccine Hesitancy: The Five C's to Tackle Behavioral and Sociodemographic Factors
Reversing and mitigating the ongoing damage associated with the COVID-19 pandemic requires that 60-70% of …
Reversing and mitigating the ongoing damage associated with the COVID-19 pandemic requires that 60-70% of the world’s population needs to be vaccinated. This article acknowledges that hesitancy is one of the most substantial hurdles to vaccination uptake at levels that would achieve herd immunity. Authors define hesitancy as “a delay in acceptance or refusal despite availability.” Five factors are proposed to tackle vaccine hesitancy, referred to as the five “C’s”: Confidence (importance, safety and efficacy…
Evidence Synthesis | Health/Medicine | North America | Decision Psychology | Preferences/Values | Health Outcomes | Infectious Diseases | Social Determinants | Culture/Society | Science/Technology -
ArticlePublication 2013Nutritional Policy Changes in SNAP: A Microsimulation and Cost-Effectiveness Analysis
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) …
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) or subsidizing fruits and vegetables purchased with SNAP. The target population was adults in the U.S. and the time horizon was 10 years. Results showed that banning SSB purchases using SNAP benefits would be expected to avert 510,000 diabetes person-years and 52,000 deaths from MIs and strokes over the next decade, with a savings of $2900 per QALY saved. A…
Cost-Effectiveness Analysis | Health/Medicine | North America | Mathematical Models | Microsimulation | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Food/Agriculture | Government/Law -
ArticlePublication 2019Cost-Effectiveness of U.S. National SSB Tax with a Multistakeholder Approach: Who Pays and Who Benefits
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) …
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) tax, overall and with stratified costs and benefits for nine distinct stakeholder groups. A microsimulation model (CVD PREDICT) was used to estimate cardiovascular disease reductions, quality-adjusted life years gained, and cost-effectiveness for U.S. adults aged 35 to 85 years, evaluating full and partial consumer price pass-through. Results showed that from both a health care and societal perspective, the SSB tax was…
Cost-Effectiveness Analysis | Health/Medicine | North America | Microsimulation | Chronic Disease/Risk | Policy/Regulation | Business/Industry | Economics/Finance | Government/Law